Soleno Therapeutics, Inc. (NASDAQ:SLNO) VP Sells $1,013,664.33 in Stock

Soleno Therapeutics, Inc. (NASDAQ:SLNO) VP Michael F. Huang sold 14,583 shares of the business’s stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the transaction, the vice president now owns 36,817 shares of the company’s stock, valued at approximately $2,559,149.67. This represents a 28.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Soleno Therapeutics Stock Down 0.8 %

Shares of SLNO stock traded down $0.54 during trading on Monday, reaching $71.45. The company’s stock had a trading volume of 4,004,984 shares, compared to its average volume of 649,585. Soleno Therapeutics, Inc. has a one year low of $36.61 and a one year high of $73.97. The business has a fifty day moving average price of $49.44 and a 200-day moving average price of $50.23. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -21.52 and a beta of -1.70.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.41). Research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Institutional Trading of Soleno Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SLNO. FMR LLC boosted its position in Soleno Therapeutics by 6,048,754.5% during the third quarter. FMR LLC now owns 665,374 shares of the company’s stock valued at $33,595,000 after purchasing an additional 665,363 shares during the last quarter. Barclays PLC raised its stake in shares of Soleno Therapeutics by 149.3% during the 3rd quarter. Barclays PLC now owns 52,545 shares of the company’s stock worth $2,652,000 after purchasing an additional 31,467 shares in the last quarter. Emerald Advisers LLC boosted its holdings in shares of Soleno Therapeutics by 85.4% in the 4th quarter. Emerald Advisers LLC now owns 580,919 shares of the company’s stock valued at $26,112,000 after buying an additional 267,585 shares during the last quarter. State Street Corp grew its stake in shares of Soleno Therapeutics by 14.2% in the third quarter. State Street Corp now owns 1,142,169 shares of the company’s stock valued at $57,668,000 after buying an additional 142,033 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Soleno Therapeutics by 13.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company’s stock worth $9,779,000 after buying an additional 24,953 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SLNO shares. Cantor Fitzgerald boosted their price target on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an “overweight” rating in a report on Thursday. Robert W. Baird boosted their target price on Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday. Guggenheim reaffirmed a “buy” rating and set a $81.00 price target (up previously from $70.00) on shares of Soleno Therapeutics in a research report on Friday. Stifel Nicolaus increased their price objective on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Laidlaw boosted their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $98.86.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.